Key facts
- This page summarizes Fred Kurland's Form 4 filing for Aridis Pharmaceuticals, Inc..
- 3 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 15 Jun 2023, 17:09.
Fred Kurland - 04 May 2023 Form 4 Insider Report for Aridis Pharmaceuticals, Inc.
- SEC form
- 4
- Accepted by SEC
- 15 Jun 2023, 17:09:18 UTC
- Prior SEC filing
- 07 Dec 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Fred Kurland
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Fred Kurland filed Form 4 for Aridis Pharmaceuticals, Inc. on 15 Jun 2023.
Change
- Previous filing in this sequence was filed on 07 Dec 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ARDS
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +4,000
- Change %
- Price
- Shares after
- 4,000
- Date
- 05 Jun 2023
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ARDS
transaction
Derivative
Stock Options
Award
- Transaction value
- $0
- Shares
- +10,000
- Change %
- +13%
- Price
- $0.000000
- Shares after
- 84,575
- Date
- 04 May 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 10,000
- Exercise price
- $0.1600
- Footnotes
- F1
ARDS
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- Shares
- -4,000
- Change %
- -50%
- Price
- Shares after
- 4,000
- Date
- 05 Jun 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 4,000
- Exercise price
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
50% of the options vest on the three month anniversary of the date of grant and the remainder vest on the six month anniversary of the date of grant.
Footnote F2
Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
Footnote F3
4,000 shares of Common Stock vested on June 5, 2023 and 4,000 will vest on 12/5/2023. In the event that the Reporting Person's employment is terminated without cause by the Issuer, the RSUs will immediately vest.